CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. clinical trials
Acquired by CSPC Pharmaceutical Group Limited, 2022 · source ↗
The registry lists 2 studies whose lead sponsor is CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 9, 2026.
Before and after it joined CSPC Pharmaceutical Group Limited
- First submitted before CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. became part of CSPC Pharmaceutical Group Limited
- 0
- First submitted after CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. became part of CSPC Pharmaceutical Group Limited
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.2 studies
Something wrong with this grouping? Tell us on the CSPC Pharmaceutical Group Limited page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All CSPC Pharmaceutical Group Limited studies →
- Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic StrokeNot yet recruitingNCT07519889
Sponsor listed in the registry: CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. · First submitted after CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. became part of CSPC Pharmaceutical Group Limited
- Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.RecruitingNCT07201688Phase 3
Sponsor listed in the registry: CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. · First submitted after CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. became part of CSPC Pharmaceutical Group Limited